Loss of smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis

Cancer Journal

Volumn 9, Issue 4, 2003, Pages 302-312

  Xie, Wen ^a   Rimm, David L ^b   Lin, Yong ^a   Shih, Weichung J ^a   Reiss, Michael ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Prognosis; Smad; Transforming growth factor

Indexed keywords

SMAD2 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; DNA BINDING PROTEIN; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN; SMAD3 PROTEIN, HUMAN; SMAD4 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL TIME; TISSUE MICROARRAY; BIOSYNTHESIS; CELL DIVISION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SURVIVAL;

CELL DIVISION; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0642306985     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200307000-00013     Document Type: Article

References (79)

1. Roberts AB, Anzano MA,Wakefield LM et al. Type β transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 1985;82:119-123.
2. Massagué J. TGF β signal transduction. Annu Rev Biochem 1998;67:753-791.
3. Kurokowa M, Lynch K, Podolsky DK. Effects of growth factors on an intestinal epithelial cell line: transforming growth factor beta inhibits proliferation and stimulates differentiation. Biochem Biophys Res Commun 1987;142:775-782.
4. Winesett MP, Ramsey GW, Barnard JA. Type II TGF(beta) receptor expression in intestinal cell lines and in the intestinal tract. Carcinogenesis 1996;17:989-995.
5. Ko TC, Beauchamp RD, Townsend CM Jr et al. Transforming growth factor-beta inhibits rat intestinal cell growth by regulating cell cycle specific gene expression. Am J Surg 1994;167:14-19;discussion 19-20.
6. Ko TC, Sheng HM, Reisman D et al. Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial cells. Oncogene 1995;10:177-184.
7. Ko TC, Yu W, Sakai T et al. TGF-beta1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression. Oncogene 1998;16:3445-3454.
8. Ciacci C, Lind SE, Podolsky DK. Transforming growth factor beta regulation of migration in wounded rat intestinal epithelial monolayers. Gastroenterology 1993;105:93-101.
9. Dignass AU, Podolsky DK. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology 1993;105:1323-1332.
10. McKaig BC, Makh SS, Hawkey CJ et al. Normal human colonic subepithelial myofibroblasts enhance epithelial migration (restitution) via TGF-beta3. Am J Physiol 1999;276:G1087-1093.
11. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999;10:303-360.
12. Zhu Y, Richardson JA, Parada LF et al. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998;94:703-714.
13. Takaku K, Oshima M, Miyoshi H et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998;92:645-656.
14. Takaku K, Miyoshi H, Matsunaga A et al. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res 1999;59:6113-6117.
15. Xu X, Brodie SG, Yang X et al. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 2000;19:1868-1874.
16. Howe JR, Roth S, Ringold JC et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis [see comments]. Science 1998;280:1086-1088.
17. Lu SL, Kawabata M, Imamura T et al. HNPCC associated with germline mutation in the TGF-beta type II receptor gene. Nat Genet 1998;19:17-18.
18. Friedman E, Gold LI, Klimstra D et al. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer.Cancer Epidemiol Biomarkers Prev 1995;4:549-554.
19. Laurent-Puig P, Blons H, Cugnenc PH. Sequence of molecular genetic events in colorectal tumorigenesis. Eur J Cancer Prev 1999;8[suppl 1]:S39-47.
20. Riggins GJ, Kinzler KW, Vogelstein B et al. Frequency of Smad gene mutations in human cancers. Cancer Res 1997;57:2578-2580.
21. Takagi Y, Koumura H, Futamura M et al. Somatic alterations of the SMAD-2 gene in human colorectal cancers. Br J Cancer 1998;78:1152-1155.
22. Takagi Y, Kohmura H, Futamura M et al. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 1996;111:1369-1372.
23. Eppert K, Scherer SW, Ozcelik H et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-552.
24. Thiagalingam S, Lengauer C, Leach FS et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-346.
25. MacGrogan D, Pegram M, Slamon D et al. Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas. Oncogene 1997;15:1111-1114.
26. Korchynskyi O, Landstrom M, Stoika R et al. Expression of Smad proteins in human colorectal cancer. Int J Cancer 1999;82:197-202.
27. Markowitz S, Wang J, Myeroff L et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability [see comments]. Science 1995;268:1336-1338.
28. Myeroff LL, Parsons R, Kim S-J et al. A transforming growth factor b type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995;55:5545-5547.
29. Parsons R, Myeroff LL, Liu B et al. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res 1995;55:5548-5550.
30. Wang J, Sun L, Myeroff L et al. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 1995;270:22044-22049.
31. Lu SL, Akiyama Y, Nagasaki H et al. Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem Biophys Res Commun 1995;216:452-457.
32. Abe T, Ouyang H, Migita T et al. The somatic mutation frequency of the transforming growth factor beta receptor type II gene varies widely among different cancers with microsatellite instability. Eur J Surg Oncol 1996;22:474-477.
33. Akiyama Y, Iwanaga R, Ishikawa T et al. Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability. Cancer 1996;78:2478-2484.
34. Ohue M, Tomita N, Monden T et al. Mutations of the transforming growth factor beta type II receptor gene and microsatellite instability in gastric cancer. Int J Cancer 1996;68:203-206.
35. Lu SL, Zhang WC, Akiyama Y et al. Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res 1996;56:4595-4598.
36. Konishi M, Kikuchi-Yanoshita R, Tanaka K et al. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer [see comments]. Gastroenterology 1996;111:307-317.
37. Renault B, Calistri D, Buonsanti G et al. Microsatellite instability and mutations of p53 and TGF-beta RII genes in gastric cancer. Human Gen 1996;98:601-607.
38. Togo G, Toda N, Kanai F et al. A transforming growth factor beta type II receptor gene mutation common in sporadic cecum cancer with microsatellite instability. Cancer Res 1996;56:5620-5603.
39. Samowitz WS, Slattery ML. Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas. Am J Pathol 1997;151:33-35.
40. Grady WM, Myeroff LL, Swinler SE et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 1999;59:320-324.
41. Xie W, Mertens JC, Reiss DJ et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 2002;62:497-505.
42. Yan W, Vellucci VF, Reiss M. Smad protein expression and activation in transforming growth factor-beta refractory human squamous cell carcinoma cells. Oncol Res 2000;12:157-167.
43. Parekh TV, Gama P, Wen X et al. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. Cancer Res 2002;62:2778-2790.
44. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-1949.
45. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Statist Assoc 1958;53:457-481.
46. Cox DR. Regression models and life-tables. J Royal Stat Soc 1972;34:187-202.
47. Wilentz RE, Iacobuzio-Donahue CA, Argani P et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-2006.
48. Wilentz RE, Su GH, Dai JL et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000;156:37-43.
49. Kern SE, Fearon ER, Tersmette KW et al. Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. JAMA 1989;261:3099-3103.
50. Jen J, Kim H, Piantadosi S et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-221.
51. Bubb VJ, Curtis LJ, Cunningham C et al. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 1996;12:2641-2649.
52. Lanza G, Matteuzzi M, Gafa R et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998;79:390-395.
53. Ogunbiyi OA, Goodfellow PJ, Herfarth K et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998;16:427-433.
54. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-1206.
55. Cardillo MR, Yap EP. TGF-beta 1 in colonic neoplasia: a genetic molecular and immunohistochemical study. Arch Anat Cytol Pathol 1996;44:241-249.
56. Tsushima H, Kawata S, Tamura S et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996;110:375-382.
57. Picon A, Gold LI, Wang J et al. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta 1. Cancer Epidemiol Biomarkers Prev 1998;7:497-504.
58. Koli K, Saharinen J, Hyytiainen M et al. Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech 2001;52:354-362.
59. Avery A, Paraskeva C, Hall P et al. TGF-beta expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer 1993;68:137-139.
60. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncogen 1993;4:493-540.
61. Jiang W, Tillekeratne MP, Brattain MG et al. Decreased stability of transforming growth factor beta type II receptor mRNA in RER+ human colon carcinoma cells. Biochemistry 1997;36:14786-14793.
62. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
63. Ko Y, Banerji SS, Liu Y et al. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells. J Cell Physiol 1998;176:424-434.
64. Matsushita M, Matsuzaki K, Date M et al. Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development. Br J Cancer 1999;80:194-205.
65. Wang J, Han W, Zborowska E et al. Reduced expression of transforming growth factor β type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem 1996;271:17366-17371.
66. Takenoshita S, Tani M, Mogi A et al. Mutation analysis of the Smad2 gene in human colon cancers using genomic DNA and intron primers. Carcinogenesis 1998;19:803-807.
67. Miyaki M, Iijima T, Konishi M et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 1999;18:3098-3103.
68. Ohtaki N, Yamaguchi A, Goi T et al. Somatic alterations of the DPC4 and Madr2 genes in colorectal cancers and relationship to metastasis. Int J Oncol 2001;18:265-270.
69. Salovaara R, Roth S, Loukola A et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 2002;51:56-59.
70. Schutte M, Hruban RH, Hedrick L et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-2530.
71. Tarafa G, Villanueva A, Farre L et al. DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination. Oncogene 2000;19:546-555.
72. Dai JL, Turnacioglu KK, Schutte M et al. Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Res 1998;58:4592-4597.
73. Carethers JM, Hawn MT, Greenson JK et al. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998;114:1188-1195.
74. Martinez-Lopez E, Abad A, Font A et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998;114:1180-1187.
75. Jernvall P, Makinen MJ, Karttunen TJ et al. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 1999;79:903-908.
76. Chan TL, Curtis LC, Leung SY et al. Early-onset colorectal cancer with stable microsatellite DNA and near-diploid chromosomes. Oncogene 2001;20:4871-4876.
77. Maitra A, Molberg K, Albores-Saavedra J et al. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol 2000;157:1105-1111.
78. Tascilar M, Skinner HG, Rosty C et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001;7:4115-4121.
79. Greene FL, Page DL, Fleming ID et al. AJCC Cancer Staging Handbook, ed. 6. New York: Springer, 2002.